Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06041529 Not yet recruiting - Clinical trials for Essential Hypertension

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Start date: September 14, 2023
Phase: Phase 4
Study type: Interventional

This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations

NCT ID: NCT06025643 Not yet recruiting - Hypertension Clinical Trials

Effects of Electrical Nervous Stimulation Transcutaneous in Hypertensive Patients

Start date: December 10, 2023
Phase: N/A
Study type: Interventional

Systemic arterial hypertension is a disease characterized by high blood pressure levels. It has a high prevalence, is a precursor of cardiovascular diseases, resulting in high costs to the health system and increased mortality. Transcutaneous electrical nerve stimulation (TENS) is a low-frequency pulsed electrical current widely used for analgesia. Recently, it has been proposed as a non-pharmacological strategy for blood pressure control. The aim of this study is to verify the effect of low-frequency TENS when applied in different anatomical sites on blood pressure, autonomic control and endothelial function in hypertensive patients.

NCT ID: NCT06019598 Recruiting - Clinical trials for Hypertension,Essential

Licorice and Home Blood Pressure, Additional Study

Start date: September 10, 2023
Phase: N/A
Study type: Interventional

Out-of-office blood pressure is more strongly associated with cardiovascular risk than office blood pressure. Licorice is known to raise blood pressure, but no previous studies have measured the effects on home blood pressure. The aim of this study is to analyze the association between licorice intake and home blood pressure.

NCT ID: NCT06018493 Recruiting - Hypertension Clinical Trials

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

NCT ID: NCT05993806 Completed - Clinical trials for Essential Hypertension

A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers

Start date: June 2, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, open, single-dose, crossover-design, phase 1, singlecenter study to evaluate bioequivalence after administration of L04RD1 or administration of L04TD3 in healthy volunteers.

NCT ID: NCT05987436 Completed - Clinical trials for Essential Hypertension

Effect of Aerobic Exercise in Patients With Essential Hypertension

Start date: November 1, 2017
Phase:
Study type: Observational

The goal of this observational study is to evaluate the effects of a supervised aerobic exercise training program on weight loss, functional capacity, quality of life (QoL), and depression levels in patients with essential hypertension.

NCT ID: NCT05972785 Active, not recruiting - Breast Cancer Clinical Trials

Long-term Use of CCB and Breast Cancer Risk

Start date: July 1, 2022
Phase:
Study type: Observational

The goal of this retrospective observational study is to examine whether long-term calcium channel blocker (CCB) use is associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands . The main questions it aims to answer are: - Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association. - Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women. The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.

NCT ID: NCT05947448 Recruiting - Clinical trials for Essential Hypertension

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Start date: January 22, 2024
Phase:
Study type: Observational [Patient Registry]

This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected

NCT ID: NCT05931224 Completed - Clinical trials for Essential Hypertension

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

Start date: June 28, 2023
Phase: Phase 3
Study type: Interventional

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

NCT ID: NCT05930028 Recruiting - Clinical trials for Essential Hypertension

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Start date: July 13, 2023
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia